Dr. Reddy's Laboratories Q3 2025 Earnings Report

Dr. Reddy's Laboratories EPS Results

• Actual EPS: $0.20
• Consensus EPS: $0.19
• Beat/Miss: Beat by +$0.01
• One Year Ago EPS: N/A

Dr. Reddy's Laboratories Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $975.71 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Dr. Reddy's Laboratories Announcement Details

• Quarter: Q3 2025
• Date: 1/23/2025
• Time: Before Market Opens

Dr. Reddy's Laboratories (NYSE:RDY), together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.